Kornimate/medical-research-clean huggingface dataset:
ptcy-atg vs atg in haploidentical hsct for acute graft-versus-host disease prophylaxis

Conditions: Hematopoietic Stem Cell Transplantation

Summary: the granulocyte colony-stimulating factor (g-csf)+antithymocyte globulin (atg)-based protocols and posttransplantation cyclophosphamide (ptcy) protocols have been widely used for graft-versus-host disease (gvhd) prophylaxis in haploidentical related donor transplantation (haplo-hsct). nevertheless, severe acute gvhd remains an obstacle for haplo-hsct. this study is aim to evaluate the efficacy of a modified protocol that includes ptcy and atg in recipients of haplo-hsct.

haploidentical related donor transplantation is now considered an important alternative to allogeneic hematopoietic stem cell transplantation (allo-hsct). currently, the strategies for graft-versus-host disease (gvhd) prophylaxis mainly include ex vivo and in vivo t-cell depletion (tcd) in haploidentical hsct (haplo-hsct). in vivo tcd modalities have become mainstream including granulocyte colony-stimulating factor (g-csf)+antithymocyte globulin (atg)-based protocols and posttransplantation cyclophosphamide (ptcy) protocols. the atg strategy has been widely used. nevertheless, severe acute gvhd remains an obstacle for haplo-hsct. in addition, infections, especially viral infections, remain an important drawback of this strategy. this study is aim to evaluate the efficacy of a modified protocol that includes ptcy and atg in recipients of haplo-hsct.

Eligibility criteria:
inclusion criteria: * a patient age of 18-65 years * haploidentical hematopoietic stem cell transplant recipient * subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)

Keywords: hematopoietic stem cell transplantation posttransplantation cyclophosphamide antithymocyte globulin viral infection graft-versus-host disease
ntm-ld treatment based on genseizer characteristic gene capture strategy

Conditions: Non - Tuberculosis Mycobacteria Lung Disease

Summary: treatment of non - tuberculosis mycobacteria lung disease is challenging. the current treatment used is from 2007 american thoracic society guidelines recommended antibiotic combination therapy, which is lack of validation of clinical studies. more and more studies have confirmed that ntm antibiotic resistant gene will affect the efficacy, such as erm(41), rrl to clarithromycin, rrs to amikacin and so on. this study aimed to compare the efficacy of guideline recommended therapy and optimized therapy according to antibiotic susceptibility - related genotype.genetic testing is accomplished through genseizer's high-throughput gene capture technique.


Eligibility criteria:
inclusion criteria: * patients met diagnostic criteria of ntm lung disease by ats/idsa on 2007 * non-cf bronchiectasis exclusion criteria: * already on treatment for ntm lung disease * appropriate exclusion of other lung diagnosis * patients with severe organ dysfunction
early jejunostomy nutrition minimizes time to chemotherapy

Conditions: Gastric Cancer; Laparoscopic Surgery; Chemotherapy

Summary: adjuvant chemotherapy (ac) for gastric cancer is known to improve prognosis, and longer time to ac is associated with worse survival. however, most clinical trials mandate that ac is still to commence within 6 to 8 weeks after surgery consideration for malnutrition, postoperative complications and intolerance of ac. placement of jejunostomy nutrition tube for enteral nutrition is a common component of these procedures, as a result of superior postoperative organ function, decreased infection rates, and a greater likelihood to complete ac with enteral nutritional support. fast-track surgery (fts) recovery program focuses on enhancing recovery and reducing morbidity. introduction of fts concepts are safe, feasible, and can achieve shorter hospital stays and reduced costs. early postoperative enteral nutrition combined with fts results in reductions in total complications compared with traditional postoperative feeding practices and does not negatively affect outcomes. however, the benefit of jejunostomy nutrition tube routine placement and combination with fts is still being debated. besides, there remains some controversy over the optimal combination of nutrients and duration and timing and routes of feed administration. the aim of this study was to determine whether fts with early jejunostomy nutrition (ejn) following laparoscopic gastrectomy for gastric cancer improved postoperative recovery and minimizes time to ac when compared with fts with early oral nutrition (eon).


Eligibility criteria:
inclusion criteria: * primary gastric cancer * r0 resection exclusion criteria: * metastatic tumor * locally unresectable tumor * previous gastric/enteral resection * age under 18 years or over 70 years * preoperative complete parenteral or enteral nutrition * neo-adjuvant chemotherapy * severe malnutrition * lack of the patient's consent for the trial participation, jejunostomy tube insertion or epidural analgesia
sexual health of obese men before and after bariatric surgery.

Conditions: Bariatric Surgery

Summary: compare male health sexual questionnaire (mhsq) before and after bariatric surgery to assess the sexual health of the obese men with a recommended and exhaustive tool. there are few data that evaluate the sexual health of this population.

the sexual dysfunctions are more commonly in the obese men population. for example, erectile dysfunction is more than twice as common as in the general population. however, the data on sexuality in the broad sense are rarer. the latter are in favor of an inconsistent improvement and use the brief male sexual function inventory. the mhsq is now recommended by the french urology association to evaluate more fully male sexuality. its relatively recent validation explains the few studies referring to. the investigators believe that one of the major determinants of sexual health in obese men is the self-image. the investigators will submit to the patients the male heath sexual questionnaire, the beck depression inventory (bdi) and the multidimensional body self relations questionnaire - appearance scales (mbsrq-as) and collect weight, bmi and age during the classic follow up. the data will be collected during the preoperative assessment as well as 6 months and 12 months postoperatively.

Eligibility criteria:
inclusion criteria: * any male patient eligible for bariatric surgery, the indication of which was decided at a multidisciplinary consultation meeting. * not opposed to research. * benefiting from social security cover. exclusion criteria: - inclusion criteria not satisfied

Keywords: obesity sexual dysfunction
photobiomodulation in oral lesions resulting from anti-neoplastic prevention

Conditions: Oral Mucositis; Osteoradionecrosis; Osteonecroses, Bisphosphonate; Osteonecrosis Due to Drugs, Jaw; Hyposalivation; Head and Neck Cancer; Oral Cancer

Summary: introduction: there are several manifestations in the oral mucosa resulting from antineoplastic treatments by chemo (qt) or radiotherapy (rt). in this study we will collect the variables referring to oral mucositis (om), radiodermatitis, osteonecrosis of the jaws (onj), hyposalivation and xerostomia, dysgeusia, pain, oral candidiasis (opportunistic infection), trismus, quality of life, oral hygiene. mo and hyposalivation, which are related to damage to the salivary glands, are the most common manifestations, and onj is the most difficult to treat. the dentist can play an important role in prevention and treatment these oral lesions, directly influencing the patient's quality of life and adherence to antineoplastic treatment. objectives: the main objective is to evaluate the efficacy of the intervention, using lll phototherapy and topical vit e, in the om. and the intervention through lll phototherapy and lprp in the onj. these interventions will be performed by dentists during antineoplastic medical treatment. material and methods: clinical trial, randomized, with balanced randomization, single-blind (for the evaluator of the results) with 2 experimental arms and a control group, carried out in a single center. group 1, intervention with lll phototherapy, group 2, intervention with application of topical vit e and group 3, mouthwash with 0.12% chlorhexidine (usual clinical information). 360 patients will participate in this study from the units of oncology medicine, radiotetaphic medicine and oral medicine, oral surgery and implantology at the university of santiago de compostela. the segment of the patients will be given, an initial visit and returns every day that hears the application of antineoplastic treatment for the group of lll phototherapy, returns of 15 days, one month, three months, six months, nine months and one year. in these return visits, evaluations and questionnaires will be carried out regarding all the variables that we will collect. predictable results: if the application of laser phototherapy or topical vit e contributes to the cessation, reduction or improvement of the clinical evolution of the manifestation of oral lesions, these treatments could be immediately implemented in our oral medicine unit and could lay the foundations for its implementation in different public centers and private.


Eligibility criteria:
inclusion criteria: * patients with head and neck or breast cancer who will undergo chemotherapy or radiotherapy. exclusion criteria: * participants who do not sign the informed consent. * patients who have been or will be treated by chemo and radiotherapy together. * patients in treatment of a cancer recurrence. * patients reporting diabetes or sjogren's syndrome.

Keywords: dentistry health promotion clinical trial oral mucositis radiotherapy chemotherapy lasertherapy phototherapy hyposalivation orn mronj
expression of programmed death ligand-1 (pd-l1) in nasopharyngeal and hyypopharyngeal carcinoma

Conditions: Nasopharyngeal and Hypopharyngeal Carcinoma

Summary: head and neck tumors comprise heterogeneous neoplasms that arise from surface epithelium of different anatomic subsites in head and neck region such as oral cavity, oropharynx, larynx and hypopharynx. nasopharyngeal and hypopharyngeal carcinomas represent 0.26 % of all cancers in egypt. tobacco exposure and alcohol dependence, and infection with oncogenic viruses such as human papilloma virus (hpv) are among the risk factors for development of these tumors. currently, the main treatment of nasopharyngeal and hypopharyngeal carcinomas is radio-chemotherapy based in histological type, grade and stages of the tumors tumor infiltrating lymphocytes (tils) are considered as cornerstone in cancer immunotherapy and as a biomarker with effectiveness predictive value. the intensity and quality of immune cells, especially lymphocytes, in tumor microenvironment are strongly related to the outcome of immune checkpoint blockade therapy .


Eligibility criteria:
inclusion criteria: * patients with nasopharyngeal and hypopharyngeal carcinomas who underwent diagnostic biopsies. exclusion criteria: * patients received chemotherapy or radiotherapy. * patients with insufficient clinical data. * specimens with extensive necrosis * tiny specimens which are insufficient for accurate diagnosis.
effects of an integrative day-care clinic program for breast cancer patients during chemotherapy

Conditions: Breast Cancer; Chemotherapy; Mind-Body-Medicine; Acupuncture; Quality of Life

Summary: the aim of the study was to evaluate a new integrative day-care clinic concept for breast cancer patients receiving chemotherapy. this is an explorative pilot study. therefore, all outcomes are analyzed exploratively.


Eligibility criteria:
inclusion criteria: * curative malignancy (breast cancer of tnm (t: primary tumor, n: regional nodes, m: metastasis) staging i-iii) * receiving chemotherapy * at least 18 years old * written informed consent * willing and physically/mentally able to participate in a six hours day care clinic program eleven times during chemotherapy. exclusion criteria: * insufficient knowledge of the german language * physical or mental disabilities resulting in ineligibility for participation in the program or filling out the questionnaires.
appropriate inhaler use of tiotropium as add-on therapy in symptomatic asthma

Conditions: Asthma

Summary: this pragmatic, two-arm, randomized controlled trial study aim to survey the inhaler errors of add-on tiotropium therapy with ics+laba in real-world practice of asthma patients and the efficacy of recheck stratage of inhaler skills. patient characteristics and inflammatory features will be evaluated prospectively for association of asthma control by add-on tiotropium.

1. the clinical efficacy of tiotropium as add-on treatment to ics with a laba have been demonstrated in clinical trials in adult patients with symptomatic asthma. 2. certain patients of daily care, like patients with smoking asthma, late onset asthma or asthma with chronic airway obstruction are often excluded from clinical trials. 3. studies have shown the cognitive function of patients with copd is impaired. when mixed types of inhaler devices are prescribed, the multiple steps of different devices may ensure complexity and confusion for patients, which may compromise the efficacy of add-on therapy. the inhaler error of add-on tiotropium treatment in real-world asthma treatment is unknown. 4. the improvement of step errors after varieties of teaching intervention is around 30\~50%. strategy of recheck inhaler technique recommended by the treatment guideline may optimized inhaler use. (https://ginasthma.org/gina-reports/). 5. factors like responseness of short-acting bronchodilators and cholinergic tone have been reported as predictors of a positive clinical response of add-on tiotropium. however, more specific physiological or inflammatory factors. e.g. exhaled nitric oxide test (feno), and para symptomatic function and cardiac-pulmonary interaction have not been evaluated prospectively. 6. this pragmatic, two-arm, randomized controlled trial study aim to survey the inhaler errors of add-on tiotropium therapy with ics+laba in real-world practice of asthma patients and the efficacy of recheck stratage of inhaler skills. patient characteristics and inflammatory features will be evaluated prospectively for association of asthma control by add-on tiotropium.

Eligibility criteria:
inclusion criteria: 1. age 20 to 75 years old asthmatic patients under regular treatment 2. received medium to high dose ics with laba at least 3 months 3. persistent asthma related symptoms: asthma control questionnaire (acq-7\>1.5) 4. physicians in charged prescribed tiotropium as add-on therapy according to clinical judgement. exclusion criteria: 1. refuse to provide inform consent 2. pregnancy or breastfeeding women 3. patients with chronic obstructive pulmonary disease 4. using other long-acting muscarinic antagonists e.g. sebree, ultibro, anoro and spiolto

Keywords: tiotropium inhaler technique asthma
external-beam radiation therapy plus implanted radiation therapy in treating patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: radiation therapy uses high-energy x-rays and other sources to damage tumor cells. giving radiation therapy in different ways may kill more tumor cells. purpose: phase ii trial to study the effectiveness of external-beam radiation therapy followed by implanted radiation therapy in treating patients who have prostate cancer.

objectives: i. determine the acute and late grade 3-5 genitourinary (gu) and gastrointestinal (gi) toxic effects of external beam radiotherapy followed by permanent source brachytherapy using interstitial iodine i 125 seeds in patients with intermediate risk, clinically localized adenocarcinoma of the prostate. ii. determine the freedom from prostate specific antigen (psa) failure, overall survival, disease specific survival, and local and/or distant clinical relapse rates in patients treated with this regimen. outline: this is a multicenter study. patients undergo external beam radiotherapy (ebrt) to the pelvis 5 days a week for 5 weeks. permanent source brachytherapy comprised of ultrasound-guided implantation of iodine i 125 seeds into the prostate is performed 2-6 weeks after completion of ebrt. patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 2 years, and then annually thereafter. projected accrual: a total of 110 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: histologically proven locally confined adenocarcinoma of the prostate clinical stage t1c-t2b, nx or n0, m0 gleason score 2-6 and psa greater than 10 ng/dl but no greater than 20 ng/dl or gleason score 7 and psa no greater than 20 ng/dl prostate volume no greater than 60 ml by transrectal ultrasound prior to external beam radiotherapy american urologic association voiding symptoms score no greater than 18 no distant metastases patient characteristics: age: over 18 performance status: zubrod 0-1 life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no hip prosthesis no other malignancy within the past 5 years except basal cell or squamous cell skin cancer no major medical or psychiatric illness that would preclude study fertile patients must use effective contraception prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy endocrine therapy: prior induction hormonal therapy allowed only if started no more than 6 months prior to study radiotherapy: see disease characteristics no prior radiotherapy to pelvis surgery: no prior transurethral resection of prostate no radical surgery for carcinoma of the prostate

Keywords: adenocarcinoma of the prostate stage i prostate cancer stage iib prostate cancer stage iia prostate cancer
the effect of hawthorn on lipoprotein cholesterol ratio in schizophrenics with antipsychotics

Conditions: Schizophrenia

Summary: importance: the problems of side effects of metabolic disturbances in schizophrenic patients have been of worldwide concern for some time. patients with dyslipidemia have an increased risk of cardiovascular diseases. a chinese herb, hawthorn, is widely used for the treatment of dyslipidemia. objective: therefore, this study aimed to investigate the effect of hawthorn on lipid profile levels in schizophrenic patients treated with antipsychotics. design, setting, and participants: a longitudinal case-control study was used in a general hospital in taiwan. a total of 59 schizophrenics treated with antipsychotics, and 76 healthy adult subjects, who were all hospital workers, were enrolled in this study. main outcomes and measures: all participants received hawthorn at a dose of 3 gm/day for six months.

the problem of metabolic disturbances in schizophrenic patients who take antipsychotics has always been a cause for global concern and discussion. although hawthorn is widely used in the treatment of heart problems and the lowering of blood lipid levels, it is unknown whether hawthorn has an effect in schizophrenic patients treated with antipsychotics. hence, there are several areas of interest in the present study: 1) the effect of hawthorn on lipid profile levels in schizophrenic patients treated with antipsychotics; 2) a comparison of lipid profile levels between schizophrenic patients and healthy adults; 3) the contributing factors that relate to changes in lipid profile levels in patients who take hawthorn.

Eligibility criteria:
inclusion criteria: * patients in case group who had to meet the diagnostic criteria for schizophrenia according to the diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv). * all participants in the case group had previously received antipsychotic treatment for a period of time. exclusion criteria: * patients who had comorbid serious medical illnesses, and may therefore present substantial clinical risk due to pharmacotherapy, were excluded from the sample * participants were pregnant and lactating women in both group, were excluded.

Keywords: hawthorn tg/hdl ratio dyslipidemia schizophrenia antipsychotics
efficacy and feasibility of ectoin® inhalation solution in inflammatory obstruction and ageing of the lung

Conditions: COPD; Particulate Matter Induced Inflammation of the Lung

Summary: to investigate the physical inflammation inhibition effects of eil (ectoin-hydro-complex) in subjects of the established salia-cohort and the preventive effects on lung function decline.


Eligibility criteria:
inclusion criteria: * postmenopausal females (75 - 80 years) * fev1/fvc \< 0,77 (in the investigation 2007/2008) * inflammatory markers tfn-alpha \> median or neutrophilic granulocytes \> median (investigation 2007/2008) * non smokers or ex smokers who have stopped smoking for longer than 6 months exclusion criteria: * participation in another clinical study in the previous month * severe concomitant disease which may have an impact on the study participation * hypersensitivity against ectoin * myocardial infarction or apoplexy within the last year * uncontrolled hypertension: systolic blood pressure \>200 mmhg or diastolic pressure \>120 mmhg * known aortic aneurysm * other respiratory diseases (e.g. cystic fibrosis, alpha-1-antitrypsin deficiency, sarcoidosis, allergic alveolitis, tuberculosis, etc.) * patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit) * on investigators decision

Keywords: particulate matter induced inflammation of the lung